Time-Limited Eating and Continuous Glucose Monitoring in Adolescents with Obesity: A Pilot Study
Overview
Authors
Affiliations
Due to its simplicity, time-limited eating (TLE) may represent a more feasible approach for treating adolescents with obesity compared to other caloric restriction regimens. This pilot study examines the feasibility and safety of TLE combined with continuous glucose monitoring (CGM) in adolescents. Fifty adolescents with BMI ≥95th percentile were recruited to complete a 12-week study. All received standard nutritional counseling, wore a CGM daily, and were randomized to: (1) Prolonged eating window: 12 h eating/12 h fasting + blinded CGM; (2) TLE (8 h eating/16 h fasting, 5 days per week) + blinded CGM; (3) TLE + real-time CGM feedback. Recruitment, retention, and adherence were recorded as indicators of feasibility. Weight loss, dietary intake, physical activity, eating behaviors, and quality of life over the course of the intervention were explored as secondary outcomes. Forty-five participants completed the study (16.4 ± 1.3 years, 64% female, 49% Hispanic, 75% public insurance). There was high adherence to prescribed eating windows (TLE 5.2 d/wk [SD 1.1]; control 6.1 d/wk [SD 1.4]) and daily CGM wear (5.85 d/wk [SD 4.8]). Most of the adolescents (90%) assigned to TLE reported that limiting their eating window and wearing a CGM was feasible without negative impact on daily functioning or adverse events. There were no between-group difference in terms of weight loss, energy intake, quality of life, physical activity, or eating behaviors. TLE combined with CGM appears feasible and safe among adolescents with obesity. Further investigation in larger samples, with a longer intervention duration and follow-up assessments are needed.
Simunovic M, Kumric M, Rusic D, Paradzik Simunovic M, Bozic J Diagnostics (Basel). 2025; 14(24.
PMID: 39767162 PMC: 11674695. DOI: 10.3390/diagnostics14242801.
Intermittent fasting as a treatment for obesity in young people: a scoping review.
Bakhsh J, Salvy S, Vidmar A NPJ Metab Health Dis. 2025; 2(1):39.
PMID: 39744147 PMC: 11685102. DOI: 10.1038/s44324-024-00041-2.
Helbling J, Ginieis R, Mortessagne P, Ruiz-Gayo M, Bakoyiannis I, Ducourneau E Mol Metab. 2024; 90:102061.
PMID: 39515608 PMC: 11609524. DOI: 10.1016/j.molmet.2024.102061.
Hegedus E, Vu M, Salvy S, Bakhsh J, Goran M, Raymond J J Acad Nutr Diet. 2024; 124(8):1014-1028.
PMID: 39464252 PMC: 11507361. DOI: 10.1016/j.jand.2023.10.012.
Xie Y, Gu Y, Li Z, He B, Zhang L Nutrients. 2024; 16(17).
PMID: 39275322 PMC: 11397086. DOI: 10.3390/nu16173007.